Publications by authors named "Rei Kamitani"
Article Synopsis
- Researchers studied the immune activity in bladder cancer (BC) by analyzing 159 samples and categorizing them into two groups: a "hot cluster" with high immune marker expression and a "cold cluster" with low expression.
- High-grade T1 tumors were often found in the hot cluster, indicating active immune responses, while tumors that progressed to muscle invasion were generally in the cold cluster, correlating with a higher risk of disease progression.
- The study identified key molecular alterations between the hot and cold clusters and emphasized the importance of maintaining immune activity after BCG therapy for recurrent non-muscle-invasive bladder cancer (NMIBC), suggesting new treatment targets.
In recent years, immune checkpoint inhibitors have attracted attention in treatment for urothelial carcinoma. However, many clinical trials included only patients who had adequate renal function. The efficacy of immune checkpoint inhibitors for hemodialysis patients had not been well-documented.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on 135 patients who had radical prostatectomy (RP) for localized prostate cancer and developed persistent prostate-specific antigen (PSA), which indicates treatment failure.
- Key findings showed that seminal vesicle invasion (SVI) and a nadir PSA of 1.0 ng/mL or higher were significant risk factors for developing castration-resistant prostate cancer (CRPC).
- Salvage radiation therapy (RT) was found to be more effective in controlling cancer than androgen deprivation therapy (ADT), with higher 10- and 15-year CRPC-free survival rates.
Background: Small cell bladder carcinoma (SCBC) is a rare and aggressive malignant tumor with no established treatment guidelines. Its treatment algorithm has been based on the small cell lung cancer (SCLC) guidelines. Metastatic SCBC has poor prognosis (even when treated with platinum-based chemotherapy, which is usually used for extensive-disease SCLC).
View Article and Find Full Text PDFArticle Synopsis
- Primary renal angiosarcoma (PRA) is a very rare and aggressive cancer, and this study focuses on identifying its prognostic factors and treatment options due to the lack of established clinical guidelines.
- The research analyzed data from 113 patients across 103 articles, finding that metastatic status at diagnosis and tumor size greater than 5 cm significantly affected disease-specific survival rates.
- The study concluded that while surgical margins and postoperative therapies didn’t notably improve outcomes, postoperative radiation for large localized tumors and systemic therapy for metastatic cases may enhance survival chances.
Background: Paratesticular leiomyosarcoma (LMS) is a rare tumor. Conventionally, tumor resection by high inguinal orchiectomy is performed as the preferred treatment approach for paratesticular sarcoma. On the other hand, testis-sparing surgery has recently attracted attention as a less-invasive treatment option for paratesticular sarcoma.
View Article and Find Full Text PDFIntroduction: The aim of this study was to validate contemporary grading systems, in particular, the Gleason grade group (GGG) 5.
Patients And Methods: We retrospectively reviewed the clinicopathologic data of 176 patients who underwent radical prostatectomy and whose pathologic results were GGG 4 or 5. The endpoints were biochemical recurrence (BCR) and castration-resistant prostate cancer (CRPC).
Introduction: Cellular angiofibroma is a benign mesenchymal tumor that is rare and has a good prognosis. However, preoperative distinction of cellular angiofibroma from malignant tumors is difficult.
Case Presentation: A 77-year-old man complained of a left inguinal mass, which was a solid, painless, mobile tumor measuring approximately 40 mm and contacted with the left spermatic cord.
Background: Liposarcoma is one of the most common subtypes of soft tissue sarcoma. Although the standard treatment for localized liposarcoma is surgical resection with negative margins, a treatment specific to paratesticular liposarcoma has yet to be quantitatively evaluated.
Methods: A systematic search of Medline, Web of Science, Embase, and Google was performed to find articles describing localized paratesticular liposarcoma published between 1979 and 2018 in English.